

Sponsors



Tenzala[®]
Enzalutamide

Trustimer[®]
Trastuzumab Deruxtecan

AryoTrust[™]
Trastuzumab

Pectuna[®]
Pertuzumab


Orchid Pharmed
Sky's the Limit

 شرکت سیناژن
CinnaGen

ARYOGEN


NAN ALVAND

PADYNEX[®]

Trastuzumab emtansine 100,160 mg

 **Palbocap[®]**

Palbociclib 75,100,125 mg

PacInab[®]
100 mg Paclitaxel
(albumin-bound particles)

TPOral[®]
eltrombopag 25,50 mg


 **simertinib-ND[®]**



RONAK



ronakpharm.com



Ronak
Oncology

ROFOLIN[®]
Calcium Folate

ZOLENA[®]
Zoledronic Acid



BARAN CHEMICAL &
PHARMACEUTICAL Co.



Xalbanib®

Crizotinib 250 mg (Capsule)

ERX CODE: 71808



Regafib®

Regorafenib 40 mg (F.C. Tablet)

ERX CODE: 67883



Nexofenib®

Sorafenib 200 mg (F.C. Tablet)

ERX CODE: 71739



Matinab®

Imatinib 100 mg (F.C. Tablet)

ERX CODE: 71467



Banolib®

Nilotinib 200 mg (Capsule)

ERX CODE: 71504

واحد حمایت از بیمار

۰۹۱۰۶۹۰۲۰۸۴

www.baranpharmaco.ir

Address: First Floor, No.4, 1st Alborz Alley, North Isargaran Street,
Yadegar-E-Imam Highway, Tehran, Iran

P.C: 19817 17165

Tel: +98 21 22072571 +98 21 22131506

Fax: +98 21 22134621



Sequencing is Key



TIME IS IN YOUR HANDS

Consider treatment sequence early on to maximize patient survival in R/M SCCHN:^{1,2}

- 1L Erbitux® + CT* followed by 2L ICI has demonstrated an mOS of up to 22.4 months and 21.9 months in clinical trials and real-world studies respectively³⁻⁵

*Platinum-based CT.

1L, first line; 2L, second line; CT, chemotherapy; ICI, immune checkpoint inhibitor; mOS, median overall survival; R/M, recurrent and/or metastatic.

1. Argiris A, et al. Front Oncol 2017;7:72 ; 2. Hwang M, Seiwert TY. Lancet Oncol 2021;4:413-415 ; 3. Guigay J, et al. Lancet Oncol 2021;4:463-475; 4. Guigay J, et al. Lancet Oncol 2021;4:463-475 (supplementary appendix); 5. Psyrri A, et al. Ann Oncol 2023;34:262-274.

© 2023 Merck KGaA, Darmstadt, Germany and/or its affiliates. All rights reserved.
NE-ERB-00104



Microreltin s.R. 11.25 mg
Triptorelin Acetate **3-month**



Microreltin s.R. 3.75 mg
Triptorelin Acetate **28-day**



Sandosphere LAR 20 mg
Octreotide




Sandosphere LAR 30 mg
Octreotide



MabThera
R i t u x i m a b



Herceptin[®]
trastuzumab



AVASTIN[®]
bevacizumab

 **Kadcyla**[®]
trastuzumab emtansine

 **PERJETA**[®]
pertuzumab


Doing now what patients need next



SOMATOM go.Sim®

SIEMENS
Healthineers

ACCURAY



CyberKnife®

Radixact®

varian

A Siemens Healthineers Company



TrueBeam®



Matlab Arefan Eng.Co
Medical Healthcare Authorized

شرکت مهندسی مطلب عارفان

تجهیزات پزشکی

تهران، میدان آرژانتین، خیابان الوند، کوچه سی و پنجم، پلاک ۸، تلفن: ۰۲۱-۸۸۶۵۱۹۵۰-۵۱

OVER 30 YEARS OF CONFIDENCE ¹⁻⁶



ZOL-405-ST-1225-1223-JRN

1. Zoladex 3.6 mg implant, FDA Label, Available on https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/019776s050/051/052lbl.pdf, last accessed 5 July 2023.
 2. Bolla M, et al., 2010. External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk. *Lancet Oncol*, Volume 11, p. 1066-73.
 3. Carrie, C. et al., 2016. Salvage radiotherapy with or without short-term hormone therapy for rising prostate-specific antigen concentration after radical prostatectomy (GETUG-AFU 16): a randomized, multicenter, open-label phase 3 trial. *Lancet Oncol*, Volume 16, pp. S1470-2045.
 4. Zapatero A, et al., 2015. High-dose radiotherapy with short-term or long-term androgen deprivation in localized prostate cancer (DART01/05 GICOR): a randomized, controlled, phase 3 trial. *Lancet Oncol*, Volume 16, p. 320-27.
 5. KARSARY, A. et al., 1991. Comparison of LHRH Analogue (Zoladex) with Orchiectomy in Patients with Metastatic Prostatic Carcinoma. *BJU*, 67(5), pp. 502-508.
 6. Vogelzang, N. et al., 1995. Goserelin versus orchiectomy in the treatment of advanced prostate cancer: Final results of a randomized trial. *Urology*, 46(2), pp. 220-226.

For any adverse event report, product quality complaint or medical information request related to AZ products, you can complete the web-based form accessible 24/7 via the URL: <http://contactazmedical.astrazeneca.com> For medical information requests, you can alternatively send to: medinfo-ne@astrazeneca.com For adverse events reporting, you can alternatively send directly to: Patientsafety.ne@astrazeneca.com Or Contact our office on Tel: +96265827580 or +9611385534. For full prescribing information, please request it from AstraZeneca representative at the exhibition stand.

**THE WAY TO
A BETTER
LIFE**

TINAGRASTTM
Filgrastim
300 Micrograms/0.5mL



TinaKidTM
Filgrastim
150 Micrograms/0.25 mL



TinaPegTM
(Pegfilgrastim)
6 mg / 0.6 mL





PATIENT POSITIONING AND GATING



PATIENT BIOMETRIC VALIDATION & PERSONAL SAFETY

SUPERFICIAL & ORTHOVOLTAGE THERAPY SYSTEMS



TREATMENT PLANNING SYSTEMS

NUCLEAR MEDICINE SYSTEMS AND PET INJECTOR



RADIOTHERAPY & IMAGING PHANTOMS

شرکت رسول زاده و شرکا

تهران - خیابان آفریقا، بلوار اسفندیار، پلاک ۲۱، کدپستی: ۱۹۶۷۹۱۷۵۹۳
تلفن: ۲۲۰۱۵۱۳۱ فکس: ۲۲۰۵۸۸۵۲

21 Esfandiar Blvd., Africa Ave., Tehran 1967917593, Iran
Tel: +98 21 22015131 Fax: +98 21 22058852
E-mail: info@rasoolzadeh.co www.rasoolzadeh.co

YOUR LIFE MATTERS

Etopodāl[®]

Etoposide 100,200 mg

Etoposide is used to treat certain form of lung cancer



Therapeutic indications:

- Testicular cancer
- Small cell lung cancer
- Hodgkin's lymphoma
- Non-Hodgkin's lymphoma
- Acute myeloid leukemia
- Gestational trophoblastic neoplasia
- Ovarian cancer



Cedal | Thinking of Patients



5th floor, No. 16, 145th St., Gisha Ave., Tehran-Iran

+98 21 86190521

info@nanocedal.com

Variopeptyl[®] 11.25

Triptorelin Pamoate



**SWISS
MADE API**



You Can Beat
Prostate Cancer

and you don't need surgery to do it.

3 month
depot

BACHEM
SWITZERLAND

V
VARIAN
PHARMED



تکنومد

ارائه پیشرفته‌ترین روش‌های
درمان سرطان

Elekta



Radiotherapy



MR/RT



Brachytherapy

We are focused
on **precision**
radiation medicine.



Treatment Planning



Oncology Informatics



Radiosurgery



TARAHEH SALAMATI FARDA
A FANAVARI AZMAYESHGARI CO.





Stereotactic Neurosurgery



Elekta Harmony



Pooyesh Darou
Biopharmaceutical Co.





PDgrastim[®]
Filgrastim, rh G-CSF derived from E-Coli



PDlasta[®]
Pegylated filgrastim

Because Life is Precious

A New Song For Life



PDpoetin[®]
4000 / 10000 I.U.

*The First and Most Trusted EPO (Epoetin **Alfa**) Biosimilar*

CONTACT US

+98 21 88 997 248 +98 21 88 969 368

NO. 13, 5th Ave, Fatemi St, Tehran, Iran

info@pooyeshdarou.com





ACTERO PRODUCTS ELECTRONIC CODES



DEVELOPING FUTURE

ACTERO PRODUCTS ELECTRONIC CODES

	Form and dosage	Code
 Bevacizumab	Vial 100 mg	71707
	Vial 400 mg	71708
 Capecitabine	Tablet 500 mg	71384
 Oxaliplatin	Vial 50 mg	71514
	Vial 100 mg	71515
 Irinotecan	Vial 100 mg	69128
 Paclitaxel	Vial 30 mg	69133
	Vial 100 mg	69132
	Vial 150 mg	70206
	Vial 300 mg	69131
 Everolimus	Tablet 5 mg	72022
	Tablet 10 mg	72337
 Palbociclib	Capsule 75 mg	72672
	Capsule 100 mg	72671
	Capsule 125 mg	72260
 Docetaxel	Vial 20 mg	69543
	Vial 80 mg	69439
	Vial 160 mg	69441
 Abiraterone	Tablet 250 mg	72332
	Tablet 500 mg	72321
 Temozolomide	Capsule 5 mg	70986
	Capsule 20 mg	71111
	Capsule 100 mg	71112
	Capsule 140 mg	71113
	Capsule 250 mg	71114

	Form and dosage	Code
 Pemetrexed	Vial 100 mg	68973
	Vial 500 mg	68819
 Erlotinib	Tablet 150 mg	71437
 Gemcitabine	Vial 200 mg	69280
	Vial 1000 mg	69279
 Carboplatin	Vial 50 mg	69199
	Vial 150 mg	69198
	Vial 450 mg	69387
 Nilotinib	Capsule 200 mg	68947
 Dasatinib	Tablet 70 mg	71848
	Tablet 100 mg	71847
 Bortezomib	Vial 3.5 mg	68555
 Lenalidomide	Capsule 10 mg	71138
	Capsule 15 mg	71139
	Capsule 25 mg	71140
 Zoledronic Acid	Vial 4 mg/5 mL	72151
 Ibrutinib	Capsule 140 mg	71464
 Rituximab	Vial 100 mg	68699
	Vial 500 mg	68895
 Bendamustine	Vial 25 mg	72590
	Vial 100 mg	65630



Neupogen®

Filgrastim (G-CSF)

AQVIDA



Your **German** Technology for Oncology Products



Non-Small Cell Lung Cancer – Metastatic Breast Cancer*



AN EFFECTIVE ORAL CHEMOTHERAPY TO START WITH^{††}



Recommended by
International Guidelines[†]

NCCN

ASCO

ESMO/ABC5



* NAVELBINE® Oral is indicated as a single agent and in combination chemotherapy for the treatment of Non-Small Cell Lung Cancer and Metastatic Breast Cancer

Navelbine Oral SmPC, August 2021

Navelbine IV SmPC, August 2021

For more detailed information about the product, refer to the complete SmPC by scanning the above QR code

[†] ASCO Guidelines for MBC, Moy et al. J Clin Oncol 2021
ASCO Guidelines, Stage I to IIIA Completely Resected NSCLC, Kris et al. J Clin Oncol. 2017/ASCO Guideline Rapid Recommendations Update.
Pisters et al. J Clin Oncol 2022, V 40, Issue 10, 1127-1129
ASCO Living Guidelines, Therapy for Stage IV NSCLC Without Driver Alterations, Singh et al. December 2022
ASCO Living Guidelines, Therapy for Stage IV NSCLC With Driver Alterations, Singh et al. December 2022
ASCO Guidelines, Management of Stage III Non-Small-Cell Lung Cancer: ASCO Guideline, Daly et al. J Clin Oncol, 22 Dec 2021
ESMO Guidelines, 2021 Early and LA NSCLC e-update in referral to Postmus et al. Ann Oncol (2017) 28 (suppl 4): iv1-iv21
ESMO Clinical Practice Guidelines, Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
Originally published in 2018 (Planchard et al.) - Ann Oncol (2018) 29 (suppl 4): iv192-iv237. Approved by ESMO Guidelines Committee. Feb 2022
ESMO Clinical Practice Guideline MBC, Gennari et al. Ann Oncol, 2021
NCCN Clinical Practice Guidelines in Oncology, Breast Cancer, V.4, 2022, June 21, 2022
NCCN Clinical Practice Guidelines in Oncology, NSCLC, V1, 2023, December 22, 2022

^{††} As proven in clinical trials


**Pierre Fabre
Oncology**

A Pierre Fabre Médicament division

SANDOZ

Making
Medical innovation
More accessible and
Affordable¹



1 - <https://www.sandoz.com/business/manufacturing-quality-and-supply>